๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Shenzhen
Clinical trial register · China

Clinical Trials in Shenzhen, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Shenzhen Geno-Immune Medical Institute43 Beijing Biotech32 Sun Yat-sen University23 Bristol-Myers Squibb19 Shenzhen University General Hospital11
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Shenzhen

576 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Autologous Tumor Infiltrating Lymphocytes (GT101 Injection) in Patients With Recurrent or Metastatic Cervical Cancer
NCT06241781Adult
Grit Biotechnology
Phase 2
83
Beijing, Fuzhou, Shenzhen, Guilin, Haโ€™erbin, Luoyang, Zhengzhou, Wuhan
2024-04-02
Recruiting
A Real-world Observational Study of a Mucosal Contouring Method for Radiation-induced Oropharyngeal Mucositis
NCT06308328Radiation-induced Oropharyngeal Mucositis, Swallowing-induced Breakthrough Pain
Nanfang Hospital, Southern Medical University
Observational
718
Guangzhou, Shaoguan, Shenzhen, Zhuhai, Shanghai, Chengdu
2024-04-01
Recruiting
Comparison of Transcatheter Edge-to-edge Repair Using Echo Only with Echo Combined with X Ray for Mitral Regurgitation (ECHO-CLIP)
NCT06684171Mitral Regurgitation
Pan Xiangbin
Not applicable
200
Shenzhen
2024-03-29
Recruiting
A Study to Evaluate the Safety and Efficacy of the Bausch + Lomb Myopia Control Lens for the Correction of Myopic Ametropia and Slowing the Progression of Myopia in Children
NCT06305663Myopia
Bausch & Lomb Incorporated
Not applicable
418
Beijing, Dongcheng, Xiamen, Haikou, Wuhan, Shanghai, Taiyuan, Shenzhen
2024-03-29
Recruiting
A Study to Evaluate 608 in Patients With Non- Radiographic Axial Spondyloarthritis (Nr-axSpA)
NCT06222671Axial Spondyloarthritis
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Phase 2
180
Beijing, Chongqing, Zhengzhou, Nanjing, Shenzhen
2024-03-22
Recruiting
TPC Versus GP Induction Chemotherapy for Nasopharyngeal Carcinoma
NCT06301165Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 2
162
Guangzhou, Dongguan, Foshan, Shenzhen, Wuhan
2024-03-19
Recruiting
Variation in the Impact of Coffee on the Metabolic Rate
NCT06432504Healthy
Shenzhen Institutes of Advanced Technology ,Chinese Academy of Sciences
Not applicable
100
Shenzhen
2024-03-06
Active, closed
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma
NCT06191744Follicular Lymphoma (FL)
DrugsEpcoritamab·Bendamustine·Vincristine·Obinutuzumab
Genmab
Phase 3
1,095
Beijing, Xiamen, Guangzhou, Shenzhen, Nanning, Zhengzhou, Wuhan, Changsha
2024-02-05
By invitation
An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of ND-003 in Patients With Advanced Solid Cancers
NCT06169579Advanced Solid Tumor
Shenzhen NewDEL Biotech, Co., Ltd
Phase 1
96
Xiamen, Lanzhou, Guangzhou, Shenzhen, Zhanjiang, Nanning, Guiyang, Wuโ€™an
2024-02-04
By invitation
Treatment of Relapsed or Refractory t(8; 21) AML With Targeted AML1-ETO Neoantigen Cytotoxic T Cells (CTL)
NCT06499025AML, t(8;21), Neoantigen
DrugsDecitabine·Cyclophosphamide
BGI, China
Phase EARLY_PHASE1
16
Shenzhen
2024-02-01
Not yet open
Anti-infection Therapy Based on mNGS Etiological Diagnosis and Infection After Liver Transplantation
NCT06212115Infection
Shenzhen Third People's Hospital
Observational
300
Shenzhen
2024-02-01
Not yet open
Comparing Astragalus Plus Gemcitabine to Gemcitabine Alone as Neoadjuvant Treatment for Pancreatic Cancer Patients
NCT06234072Pancreatic Cancer
DrugsGemcitabine alone·Gemcitabine
Shenzhen University General Hospital
Phase 2
120
Shenzhen
2024-02
Recruiting
Individualized Neoantigen Therapy with Unusual Radiotherapy Enhancement (iNATURE)
NCT06314087Advanced Tumors
The University of Hong Kong-Shenzhen Hospital
Phase 2
154
Shenzhen
2024-01-31
Recruiting
Effects of SGLT2 Inhibitors in Pre-heart Failure Populations With Hypertension
NCT06055452Pre-Heart Failure, Hypertension
China National Center for Cardiovascular Diseases
Phase 4
120
Beijing, Shenzhen
2024-01-19
Recruiting
PRevention of OsTEoporotiC FracTure 2 Pilot Study
NCT06134908Fragility Fracture
Third Affiliated Hospital, Sun Yat-Sen University
Not applicable
50
Changsha, Dongguan, Guangzhou, Hangzhou, Hefei, Shenzhen
2024-01-13
Active, closed
A Study to Evaluate Adverse Events and Change in Disease Activity With the XEN45 Glaucoma Treatment System Implantation In Adult Participants With Open-Angle Glaucoma in China
NCT05821855Open-angle Glaucoma, OAG
AbbVie
Phase 4
120
Beijing, Fuzhou, Xiamen, Guangzhou, Shenzhen, Wuhan, Qingdao, Chengdu
2024-01-09
Active, closed
Phase 3 Study of ALXN1850 Versus Placebo in Adolescent and Adult Participants With HPP Who Have Not Previously Been Treated With Asfotase Alfa
NCT06079281Hypophosphatasia
DrugALXN1850
Alexion Pharmaceuticals, Inc.
Phase 3
124
Beijing, Changsha, Chengdu, Nanchang, Qingdao, Shanghai, Shenzhen
2024-01-03
Not yet open
China National Study of Adrenal Venous Sampling
NCT06192238Hyperaldosteronism
Chinese Academy of Medical Sciences, Fuwai Hospital
Observational
1,500
Beijing, Chongqing, Xiamen, Lanzhou, Foshan, Guangzhou, Shenzhen, Nanning
2024-01-01
Recruiting
Impact of Iron Deficiency Anemia on Neurobehavioral and Cognitive Development in Children Aged 6 to 24 Months
NCT06662045Iron-Deficiency Anemia, Neurobehavioral Manifestations, Growth Disorders, Nutritional Status
Pingshan District Maternal & Child Healthcare Hospital of Shenzhen
Observational
1,000
Shenzhen
2024-01-01
Recruiting
Efficacy and Safety of MSLN CAR-T in Advanced Malignant Tumors
NCT07399769Advanced Solid Malignant Tumors (With Positive Expression of MSLN in Tumor Tissue)
Shenzhen University General Hospital
Phase 1/2
20
Shenzhen
2024-01-01
Recruiting
Efficacy and Safety of Upadacitinib in Inflammatory Bowel Disease
NCT06780683Inflammatory Bowel Disease, Crohn's Disease, Ulcerative Colitis
DrugUpadacitinib
Xiang Gao
Observational
174
Guangzhou, Meizhou, Shenzhen, Liuzhou, Nanning
2024-01-01
Recruiting
Sintilimab in Combination with Cetuximab and Chemotherapy As First-line Treatment for RAS/BRAF Wild-type Advanced Colorectal Cancer
NCT06776757Metastatic Colorectal Cancer
DrugsPemetrexed·Tislelizumab
Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center
Phase 1/2
30
Shenzhen
2023-12-25
Active, closed
Observational Study to Evaluate the Effect and Safety of Selumetinib in Pediatric Patients With NF1-PNs
NCT06175637Neurofibroma, Plexiform
AstraZeneca
Observational
409
Beijing, Chongqing, Lanzhou, Guangzhou, Shenzhen, Nanning, Guiyang, Shijiazhuang
2023-12-20
Active, closed
Real-World Effectiveness of Dupilumab in Patients With Prurigo Nodularis: An Observational Study
NCT05991323Prurigo Nodularis
DrugDupilumab
Sanofi
Observational
100
Guangzhou, Xi'an, Jinan, Hangzhou, Wenzhou, Beijing, Shanghai, Shenzhen
2023-12-12
Recruiting
Mesenchymal Stem Cells Treatment for AIDS Patients at Late Stage
NCT05939167AIDS
Cell Energy Life Sciences Group Co. LTD
Phase 1/2
150
Beijing, Shenzhen, Shijiazhuang
2023-12-10
Not yet open
Investigator-initiated Phase I Exploratory Clinical Study of the Safety, Tolerability, and Efficacy of BST02 Injection in the Treatment of Locally Advanced/Metastatic Liver Cancer
NCT06173726Locally Advanced/Metastatic Liver Cancer
BioSyngen Pte Ltd
Phase EARLY_PHASE1
6
Shenzhen
2023-12-05
Recruiting
Neoadjuvant Anti-PD-1 Immunotherapy With Chemotherapy in Resectable Locally Advanced Oral Squamous Cell Carcinoma
NCT05798793Oral Squamous Cell Carcinoma
DrugTislelizumab
Hospital of Stomatology, Wuhan University
Phase 3
309
Shenzhen, Wuhan, Changsha
2023-11-21
Active, closed
Study of TT-00420 (Tinengotinib) in Subjects With Cholangiocarcinoma Who Failed or Relapsed to Chemotherapy and FGFR Inhibitor
NCT06057571Cholangiocarcinoma Metastatic
DrugTinengotinib
TransThera Sciences (Nanjing), Inc.
Phase 2
50
Hefei, Beijing, Fuzhou, Guangzhou, Shenzhen, Shijiazhuang, Harbin, Zhengzhou
2023-11-17
Recruiting
A Study of Efficacy and Safety of Hemay005 Tablets in Patients With Behรงet's Disease
NCT06145893Behรงet's Disease
Ganzhou Hemay Pharmaceutical Co., Ltd
Phase 3
162
Beijing, Xiamen, Guangzhou, Shenzhen, Guilin, Shijiazhuang, Xinxiang, Nanchang
2023-11-13
Recruiting
A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Antiviral Activity of Maribavir for the Treatment of Cytomegalovirus (CMV) Infection in Children and Adolescents Who Have Received a Hematopoietic Stem Cell Transplant (HSCT) or a Solid Organ Transplant (SOT)
NCT05319353Cytomegalovirus (CMV)
DrugMaribavir
Takeda
Phase 3
80
Beijing, Guangzhou, Shenzhen, Shanghai, Tianjin
2023-11-13
Not yet open
Effect of Orexin System on Nicotine Addiction and Its Neural Mechanism
NCT05947162Tobacco Use Disorder
Shenzhen Kangning Hospital
Not applicable
150
Shenzhen
2023-11-01
Active, closed
A Randomized, Double-blind 2-arm, Followed by an Open-label 1-arm, NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome.
NCT05985915Sjogrens Syndrome
DrugIanalumab
Novartis Pharmaceuticals
Phase 3
612
Hefei, Chongqing, Guangzhou, Shenzhen, Wuhan, Baotou, Nanjing, Nanchang
2023-10-27
Active, closed
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis
NCT06025578Progressive Pulmonary Fibrosis
DrugAdmilparant
Bristol-Myers Squibb
Phase 3
1,057
Hefei, Beijing, Lanzhou, Guangzhou, Shenzhen, Shenzhen Shi, Zhengzhou, Shijiazhuang
2023-10-25
Recruiting
A Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma
NCT06049290Relapsed/Refractory Multiple Myeloma
Nanjing Leads Biolabs Co.,Ltd
Phase 1/2
342
Wuhu, Beijing, Xiamen, Guangzhou, Shenzhen, Guiyang, Haikou, Luoyang
2023-10-20
Recruiting
A Study to Efficacy and Safety of SPH4336 Monotherapy or in Combination With Cadonilimab in Patients With Advanced Solid Tumors.
NCT05944224Advanced Solid Tumors
DrugsSPH4336·Cadonilimab
Shanghai Pharmaceuticals Holding Co., Ltd
Phase 1/2
63
Fuzhou, Guangzhou, Zhengzhou, Wuhan, Changsha, Yongzhou, Shenzhen, Xiโ€™an
2023-10-17
Recruiting
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata
NCT06012240Alopecia Areata
DrugUpadacitinib
AbbVie
Phase 3
1,500
Beijing, Chongqing, Guangzhou, Shenzhen, Wuhan, Nanchang, Changchun, Xi'an
2023-10-11
Active, closed
Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes
NCT06008756Arteriosclerosis, Hypercholesterolaemia
DrugEnlicitide Decanoate
Merck Sharp & Dohme LLC
Phase 3
14,550
Hefei, Beijing, Chongqing, Foshan, Guangzhou, Huizhou, Jiangmen, Shenzhen
2023-10-09
By invitation
A Long-Term Extension Study to Learn More About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus
NCT06044337Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus
DrugLitifilimab
Biogen
Phase 3
306
Beijing, Shenzhen, Dongguan, Guangzhou, Changsha, Nanjing, Shanghai, Kunming
2023-10-03
Recruiting
Efficacy and Safety of CD19CD20-CAR.p40-T in B-cell Lymphoma
NCT07097207Relapsed/Refractory B-cell Lymphoma
Shenzhen University General Hospital
Phase 1/2
20
Shenzhen
2023-10-01
Recruiting
Phase โ… /โ…ก Clinical Study to Evaluate ABO2011 in Advanced Solid Tumors
NCT06088004Solid Tumor, Adult
DrugTislelizumab
Suzhou Abogen Biosciences Co., Ltd.
Phase 1/2
218
Beijing, Guangzhou, Nanning, Shanxi, Shenzhen
2023-09-28
Recruiting
To Evaluate the Efficacy, Safety, and PK Characteristics of FCN-159 in Pediatric Patients With Refractory/Recurrent LCH
NCT05997602Langerhans Cell Histiocytosis, LCH
DrugFCN-159
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Phase 2
56
Beijing, Chongqing, Guangzhou, Shenzhen, Zhengzhou, Wuhan, Chengdu, Hangzhou
2023-09-28
Active, closed
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis
NCT06003426Idiopathic Pulmonary Fibrosis
DrugAdmilparant
Bristol-Myers Squibb
Phase 3
1,255
Hefei, Beijing, Guangzhou, Shenzhen, Shenzhen Shi, Zhengzhou, Shijiazhuang, Yichang Shi
2023-09-14
Recruiting
Efficacy and Safety of Recombinant Human FGF21-Fc Fusion Protein for Injection (TQA2225/AP025) in Adult Subjects With Non-alcoholic Steatohepatitis (NASH)
NCT06569524Non-alcoholic Steatohepatitis
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 2
120
Lu'an, Beijing, Fuzhou, Xiamen, Wuwei, Shenzhen, Liuzhou, Yulin
2023-09-14
Recruiting
Perioperative Dexmedetomidine and Long-term Survival After Cancer Surgery
NCT06030804Elderly, Cancer Surgery, Dexmedetomidine, Long-Term Survivors
Peking University First Hospital
Not applicable
4,532
Hefei, Beijing, Chongqing, Fuzhou, Jinjiang, Guangzhou, Shenzhen, Nanning
2023-09-12
Active, closed
A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjรถgren's Syndrome
NCT05946941Sjรถgren's Syndrome
DrugDeucravacitinib
Bristol-Myers Squibb
Phase 3
774
Beijing, Xiamen, Guangzhou, Shenzhen, Zhengzhou, Wuhan, Changsha, Hohhot
2023-09-11
Recruiting
An Efficacy and Safety Study of Sodium Oligomannate (GV-971) for the Treatment of Alzheimer's Disease
NCT05908695Alzheimer's Disease
DrugSodium Oligomannate
Green Valley (Shanghai) Pharmaceuticals Co., Ltd.
Phase 4
1,312
Huainan, Beijing, Xiamen, Guangzhou, Shenzhen, Nanning, Shijiazhuang, Tangshan
2023-08-31
Recruiting
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)
NCT06126224Psychosis Associated With Alzheimer's Disease
DrugKarXT
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
500
Hefei, Beijing, Chongqing, Guangzhou, Shenzhen, Nanjing, Nanchang, Shanghai
2023-08-28
Recruiting
A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma
NCT06023589Asthma
DrugTezepelumab
AstraZeneca
Phase 3
231
Beijing, Changchun, Hohhot, Lanzhou, Nanjing, Shanghai, Shenyang, Shenzhen
2023-08-24
Recruiting
BCMA-GPRC5D CAR-T Therapy in Relapsed or Refractory Multiple Myeloma
NCT06644443Multiple Myeloma in Relapse
Shenzhen University General Hospital
Phase 1/2
10
Shenzhen
2023-07-15
Recruiting
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
NCT05980949Psychosis Associated With Alzheimer's Disease
DrugKarXT
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
1,000
Hefei, Beijing, Chongqing, Guangzhou, Shenzhen, Nanjing, Zhenjiang, Nanchang
2023-07-11
Active, closed
A Study of Zigakibart in Adults With IgA Nephropathy
NCT05852938IgA Nephropathy, Immunoglobulin A Nephropathy
Novartis Pharmaceuticals
Phase 3
383
Hefei, Beijing, Foshan, Guangzhou, Shenzhen, Nanning, Guiyang, Wuhan
2023-07-06
Active, closed
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
NCT05827016Multiple Myeloma
DrugsIberdomide·Lenalidomide
Bristol-Myers Squibb
Phase 3
1,230
Hefei, Beijing, Chongqing, Guangzhou, Shenzhen, Zhengzhou, Changsha, Nanjing
2023-06-22
Active, closed
FCN-159 in Adult Patients With Symptomatic, Inoperable Neurofibromatosis Type 1-Related Plexiform Neurofibromas
NCT05913037Neurofibromatosis 1, Plexiform Neurofibroma, NF1
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Phase 3
167
Beijing, Guangzhou, Shenzhen, Shijiazhuang, Wuhan, Shenyang, Shanghai, Chengdu
2023-06-20
Active, closed
A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
NCT05869903Obesity, Overweight, Overweight or Obesity
DrugOrforglipron
Eli Lilly and Company
Phase 3
3,127
Hefei, Beijing, Chongqing, Shenzhen, Haikou, Harbin, Luoyang Shi, Zhengzhou
2023-06-05
Recruiting
Thymosin Alpha 1 Combined With Anti-PD-1 Monoclonal Antibody in Elderly Patients With Advanced Melanoma
NCT07644897Melanoma, Immune-related Adverse Event, Immune Checkpoint Inhibitor
Sun Yat-sen University
Phase 2
55
Guangzhou, Shenzhen
2023-05-30
Recruiting
PPI Infusion Versus Oral Acid Pump Inhibitors for Bleeding Peptic Ulcers
NCT05582174Upper GI Bleeding, Proton Pump Inhibitors
DrugsNexium·Esomeprazole·Vonoprazan
Chinese University of Hong Kong
Phase 4
594
Guangzhou, Shenzhen, Yangjiang, Zhuhai, Hong Kong
2023-05-18
Active, closed
A Study to Examine the Efficacy and Safety of Zanubrutinib Given to Adults With Primary Membranous Nephropathy
NCT05707377Primary Membranous Nephropathy
DrugsTacrolimus·Zanubrutinib
BeOne Medicines
Phase 2/3
178
Beijing, Fuzhou, Xiamen, Guangzhou, Shenzhen, Nanning, Guiyang, Shijiazhuang
2023-04-17
Recruiting
Post-market European & Asian Registry to Evaluate the Minosโ„ข Stent-Graft and Delivery System in Abdominal Aortic Aneurysm Treatment
NCT07674173Endovascular Repair of Infrarenal Abdominal Aortic Aneurysm Using Endovascular Stent Graft
Shanghai MicroPort Endovascular MedTech๏ผˆGroup๏ผ‰Co., Ltd
Observational
200
Lanzhou, Meizhou, Shenzhen, Changsha, Xiangtan, Yueyang, Zibo, Binhai
2023-03-05
Active, closed
A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)
NCT05722015Metastatic Non-small Cell Lung Cancer
DrugsPembrolizumab Formulated with Berahyaluronidase Alfa·Filgrastim·Taxol·Nab-paclitaxel
Merck Sharp & Dohme LLC
Phase 3
377
Hefei, Beijing, Wanzhou, Fuzhou, Guangzhou, Jiangmen, Shenzhen, Wuhan
2023-02-14
Active, closed
Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP)
NCT05653349Primary Immune Thrombocytopenia (ITP)
DrugIanalumab
Novartis Pharmaceuticals
Phase 3
226
Beijing, Guangzhou, Shenzhen, Shijiazhuang, Luoyang, Zhengzhou, Changzhou, Nanchang
2023-02-03
Active, closed
A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)
NCT05617677Systemic Lupus Erythematosus
DrugDeucravacitinib
Bristol-Myers Squibb
Phase 3
516
Bengbu, Beijing, Xiamen, Guangzhou, Shenzhen, Baoding, Luoyang, Zhengzhou
2023-01-12
Active, closed
To Evaluate the Safety, Tolerability and Pharmacokinetic of SAL0133 Tablets in Chinese Adult Healthy Subjects
NCT07030504Pharmacokinetics
Shenzhen Salubris Pharmaceuticals Co., Ltd.
Phase 1
72
Shenzhen
2023-01-10
Active, closed
Adult Spinal Muscular Atrophy (SMA) China Registry
NCT05618379Muscular Atrophy, Spinal
Biogen
Observational
200
Beijing, Fuzhou, Guangzhou, Shenzhen, Shijiazhuang, Changsha, Suzhou, Nanchang
2023-01-06
Recruiting
Real-World Effectiveness and Safety of Upadacitinib Plus Vedolizumab vs Upadacitinib Monotherapy During Induction in Moderate-to-Severe Ulcerative Colitis
NCT07442045Ulcerative Colitis (UC)
Sixth Affiliated Hospital, Sun Yat-sen University
Observational
150
Foshan, Guangzhou, Shenzhen
2023-01-01
Recruiting
Study of NY-ESO-1 TCR-T in Advanced Soft Tissue Sarcoma
NCT05620693Advanced Soft-tissue Sarcoma
Shenzhen University General Hospital
Not applicable
20
Shenzhen
2022-11-11
Active, closed
A First-in-human Study to Learn How Safe the Study Drug BAY2965501 is, Find the Best Dose (Single Drug & Combination), How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, How it Acts on Different Tumors in Participants With Advanced Solid Tumors
NCT05614102Advanced Solid Tumors
DrugPembrolizumab
Bayer
Phase 1
284
Beijing, Shenzhen, Hangzhou
2022-11-04
Active, closed
Safety and Efficacy Evaluation of BRL-101 in Subjects With Transfusion-Dependent ฮฒ-Thalassemia
NCT05577312Beta-Thalassemia
Bioray Laboratories
Phase 1/2
39
Guangzhou, Guanzhou, Shenzhen, Nanning, Changsha, Tianjin
2022-11-02
Recruiting
Study of GPC-3 CAR-T Cells in Treating With Hepatocellular Carcinoma
NCT05620706Advanced Hepatocellular Carcinoma
Shenzhen University General Hospital
Not applicable
20
Shenzhen
2022-11-01
Recruiting
Tislelizumab Combined With Chemotherapy Followed by Surgery Versus Up-front Surgery in Resectable Head and Neck Squamous Cell Carcinoma (REDUCTION-I)
NCT05582265Head and Neck Squamous Cell Carcinomas
DrugsCarboplatin (adjuvant๏ผ‰·Cisplatin ๏ผˆneoadjuvant๏ผ‰·Cisplatin๏ผˆadjuvant๏ผ‰·Nab-paclitaxel ๏ผˆneoadjuvant๏ผ‰
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 3
537
Guanzhou, Zhongshan, Shenzhen
2022-10-28
Active, closed
A Study to Evaluate Luspatercept (ACE-536) in Chinese Participants Who Require Regular Red Blood Cell Transfusions Due to Beta (ฮฒ)-Thalassemia.
NCT05567458Beta-thalassemia
DrugLuspatercept
Bristol-Myers Squibb
Phase 2
94
Maoming, Shenzhen, Liuzhou, Nanning, Haikou, Kunming, Guangzhou
2022-10-17
Recruiting
Neuraxial Labor Analgesia and Offspring Neurodevelopment
NCT04964206Pregnant Women, Labor Pain, Analgesia, Epidural, Infants
Dong-Xin Wang
Observational
4,645
Beijing, Shenzhen
2022-10-14
Recruiting
Efficacy of Trastuzumab Deruxtecan in Metastatic Breast Cancer With Different HER2 Expression Patterns
NCT06551220Metastatic Breast Cancer
DrugTrastuzumab deruxtecan
Sun Yat-sen University
Observational
800
Fuzhou, Dongguan, Foshan, Guangzhou, Shantou, Shaoguan, Shenzhen, Zhongshan
2022-10-10
Recruiting
CD7 CAR-T Cells in T-cell Lymphoma/Leukemia
NCT05620680T Lymphoblastic Leukemia/Lymphoma
Shenzhen University General Hospital
Not applicable
20
Shenzhen
2022-10-01
Recruiting
Treatment of Advanced Malignant Solid Tumors With Claudin18.2CAR-T
NCT05620732Advanced Pancreatic Carcinoma, Advanced Gastric Carcinoma
Shenzhen University General Hospital
Not applicable
20
Shenzhen
2022-10-01
Active, closed
Parent-implemented Social Communication Treatment in Autism
NCT05635760Autism, Social Communication, Speech Therapy, Parenting
Chinese University of Hong Kong
Not applicable
112
Shenzhen
2022-10-01
Recruiting
Chinese AntiphosPholipid Syndrome cohorT cOllaborative NEtworks
NCT05230017Anti Phospholipid Syndrome
Peking Union Medical College Hospital
Observational
2,000
Beijing, Fuzhou, Guangzhou, Shenzhen, Nanning, Hohhot, Nanjing, Nanchang
2022-10-01
Active, closed
HMPL-523 (Sovleplenib) in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia
NCT05535933Warm Antibody Autoimmune Hemolytic Anemia
Hutchmed
Phase 2/3
111
Fuyang, Fuzhou, Lanzhou, Guangzhou, Shenzhen, Zhanjiang, Guilin, Haikou
2022-09-30
Recruiting
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
NCT05519085Relapsed or Refractory Multiple Myeloma
DrugsMezigdomide·Bortezomib·Pomalidomide·Dexamethasone
Celgene
Phase 3
810
Beijing, Chongqing, Xiamen, Guangzhou, Shenzhen, Liuzhou, Nanning, Shijiazhuang
2022-09-20
Active, closed
A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus
NCT05531565Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus
DrugLitifilimab
Biogen
Phase 2/3
450
Beijing, Chongqing, Fuzhou, Dongguan, Guangzhou, Shenzhen, Zhongshan, Nanyang
2022-09-13
Active, closed
Study Evaluating LDL-C Change and Adherence to Inclisiran Lipid-lowering Therapy in ASCVD
NCT05399992Primary Hypercholesterolemia, Mixed Dyslipidemia
Novartis Pharmaceuticals
Observational
847
Shenzhen
2022-09-12
Recruiting
Establishment of a Decision Aid Tool for Asymptomatic Small Leiomyoma and Analysis of Influencing Factors for Clinical Decision-making Using HIFU
NCT05500118Leiomyoma, Uterine, High-Intensity Focused Ultrasound Ablation, Patients Decision Aids
Shenzhen Maternity & Child Healthcare Hospital
Observational
120
Shenzhen
2022-08-31
Recruiting
China HeadAche DIsorders RegiStry
NCT05334927Headache Disorders, Primary, Migraine, New Daily Persistent Headache, Medication Overuse Headache
DrugEptinezumab
Beijing Tiantan Hospital
Observational
10,000
Anqing, Wuhu, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Shenzhen
2022-08-29
Active, closed
An Efficacy and Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy in Chinese Participants With Acute Myeloid Leukemia in Complete Remission
NCT05413018Leukemia, Myeloid, Acute
Bristol-Myers Squibb
Phase 2
34
Hefei, Beijing, Chongqing, Guangzhou, Shenzhen, Shijiazhuang, Xuzhou, Shenyang
2022-08-19
Recruiting
A Study of JAB-21822 in Advanced or Metastatic NSCLC With KRAS p.G12C and STK11 Co-mutation and Wild-type KEAP1
NCT05276726Non-small Cell Lung Cancer
DrugGlecirasib
Allist Pharmaceuticals, Inc.
Phase 1/2
104
Beijing, Chongqing, Xiamen, Shenzhen, Nanning, Shijiazhuang, Harbin, Zhengzhou
2022-08-17
Active, closed
A Study of GNC-038, a Tetra-specific Antibody, in Participants With R/R Diffuse Large B-cell Lymphoma (DLBCL)
NCT05192486Diffuse Large B-cell Lymphoma
DrugGNC-038
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1/2
12
Shenzhen, Baoding, Luoyang, Shanghai
2022-08-10
Recruiting
Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V
NCT05268289Lupus Nephritis
DrugIptacopan
Novartis Pharmaceuticals
Phase 2
240
Nanning, Wuhan, Shenyang, Yinchuan, Beijing, Shenzhen
2022-08-10
Not yet open
Short-course Radiotherapy Followed by Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer
NCT05484024Rectal Neoplasms Malignant, Radiotherapy
DrugTislelizumab
Chinese Academy of Medical Sciences
Phase 2/3
588
Beijing, Shenzhen
2022-08-06
Active, closed
Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA)
NCT05263934Eosinophilic Granulomatosis With Polyangiitis
DrugsMepolizumab·Depemokimab
GlaxoSmithKline
Phase 3
163
Beijing, Guangzhou, Hefei, Nanjing, Qingdao, Shanghai, Shenzhen, Wenzhou
2022-07-14
Active, closed
Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis
NCT05126277Lupus Nephritis
DrugIanalumab
Novartis Pharmaceuticals
Phase 3
452
Guangzhou, Shantou, Shenzhen, Liuzhou, Haikou, Wuhan, Changsha, Nanjing
2022-07-14
Active, closed
INSPIRIS China PMCF Study
NCT05404880Aortic Valve Replacement
Edwards Lifesciences
Observational
255
Hefei, Beijing, Xiamen, Guangzhou, Shenzhen, Zhengzhou, Nanjing, Xiโ€™an
2022-07-13
Recruiting
Non-invasive Filling Pressure(NIFP) Device Based on Low Frequency Heart Sound in Assessment of Congestion in Heart Failure Patients
NCT06593223Heart Failure
The University of Hong Kong-Shenzhen Hospital
Observational
400
Shenzhen
2022-07-01
Active, closed
TAB014 Compared to Lucentisยฎ in Patients with Neovascular Age-related Macular Degeneration
NCT05461339Neovascular Age-related Macular Degeneration
BioDlink Biopharm Co., Ltd.
Phase 3
488
Hefei, Beijing, Jilin City, Chongqing, Fuzhou, Guangzhou, Shantou, Shenzhen
2022-06-28
Active, closed
Application of Polygenic Methylation Markers in Postoperative Recurrence Monitoring of Colorectal Cancer
NCT05444491Colorectal Cancer
Singlera Genomics Inc.
Observational
800
Beijing, Chengdu, Guangzhou, Haerbin, Shanghai, Shenzhen, Taiyuan
2022-06-20
By invitation
An Extension Study to Learn More About the Long-Term Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus
NCT05352919Systemic Lupus Erythematosus (SLE)
DrugLitifilimab
Biogen
Phase 3
864
Beijing, Dongguan, Guangzhou, Shenzhen, Zhongshan, Haikou, Shijiazhuang, Changsha
2022-06-10
By invitation
Significance of MRD After Surgery in Driver Gene-positive and Driver Gene-negative Stage IB-IIA NSCLC
NCT05441566NSCLC MRD ctDNA
Shenzhen People's Hospital
Observational
60
Shenzhen
2022-06-01
Recruiting
Effect of HPV Integration on Prognosis of Young Women With CIN2 in China
NCT05282095Cervical Intraepithelial Neoplasia, HPV Infection, Virus Integration, HSIL, High Grade Squamous Intraepithelial Lesions
Fujian Maternity and Child Health Hospital
Observational
300
Fuzhou, Longyan, Ningde, Putian, Sanming, Zhangzhou, Lanzhou, Shenzhen
2022-06-01
Recruiting
the Safety and Efficacy Evaluation of HGI-001 Injection in Patients With Transfusion-Dependent ฮฒ-Thalassemia
NCT05864170ฮฒ-thalassemia
Shenzhen Hemogen
Phase EARLY_PHASE1
3
Shenzhen
2022-05-27
Active, closed
A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer
NCT05353257Limited-Stage Small Cell Lung Cancer
DrugsCarboplatin/cisplatin-etoposide·Serplulimab
Shanghai Henlius Biotech
Phase 3
511
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Shenzhen, Guilin
2022-05-17
Recruiting
Observational Study of Pediatric Rheumatic and Immunologic Diseases in China: The CAPRID Registry
NCT06417502Autoimmune Diseases, Autoinflammatory Diseases
Peking Union Medical College Hospital
Observational
20,000
Beijing, Chongqing, Shenzhen, Changsha, Nanjing, Hangzhou
2022-04-29
Recruiting
Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation
NCT05288205KRAS P.G12C, Non-small Cell Lung Cancer, Colorectal Cancer, Pancreatic Ductal Carcinoma
DrugsJAB-3312·Glecirasib
Allist Pharmaceuticals, Inc.
Phase 1/2
240
Hefei, Beijing, Fuzhou, Xiamen, Guangzhou, Shenzhen, Harbin, Zhengzhou
2022-04-14
Rows per page Showing 401–500 of 576
Previous 3 4 5 6 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/city/shenzhen?page=5

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 576 of those studies with a site in Shenzhen.

How many clinical trials are recruiting in Shenzhen?

337 of the 576 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 115 have not yet opened recruitment, 109 are active but closed to new participants, and 15 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.